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The  present  study  sought  to describe  clinical  presentation  in  extranodal  lymphoma  of the  head  and  neck
(ELHN),  with  the  aim  of  improving  diagnostic  management.
Material  and  methods:  A  single-center  retrospective  observational  study  was  conducted  over  the period
2001–13.  Age,  gender,  histologic  type,  location,  type  of  clinical  presentation,  time  interval  between
symptom  onset  and  histologic  diagnosis  and  presence  of speciﬁc  symptoms  were  recorded,  as  were
the  specialty  of the  physician  initially  consulted  and  of  the  physician  taking  the  diagnostic  sample.
Results:  Sixty-seven  cases  of ELHN  were  diagnosed:  39  male  and  28  female  patients,  with  a  median  age  of
68 years.  B-cell  lymphoma  (84%)  was  more  frequent  than  plasmacytoma  (7%)  or T-cell  lymphoma  (6%).
Location  was  mainly  palatine  tonsil  (28%),  nasal  fossa  and  sinus  (19%),  nasopharynx  (14%) or  parotid
(13%).  Revelation  often  involved  a mass  (33%),  and  only  rarely  any  speciﬁc  symptoms  (9%). Time  interval
from  symptom  onset  to  diagnosis  was  short  in  aggressive  lymphoma  and  longer  in  low-grade  lymphoma
(mean  4 and  10  months  respectively).  The  physician  initially  consulted  was  an  ENT  specialist  in  67% of
cases,  and  an  ENT  specialist  performed  diagnostic  sampling  in  97%  of  cases.
Conclusion:  ELHN  is a rare  pathology  (5  cases  per year  in  our  department)  of highly  variable  clinical  pre-
sentation  depending  on  location  and  histologic  type.  The  ENT physician  should  be  prepared  for  diagnosis
regardless  of  anatomic  location,  so  as to  optimize  diagnostic  management.
©  2014  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
Hodgkin and non-Hodgkin lymphoma is the third most frequent
alignant tumor of the head and neck region (12%), following
quamous cell carcinoma (46%) and thyroid carcinoma (33%) [1].
ncidence has been rising for several decades. There are some
0,000 new cases of non-Hodgkin lymphoma of whatever loca-
ion per year in France, slightly more than half occurring in male
ubjects. Twenty-three percent of non-Hodgkin and 4% of Hodgkin
ymphomas of the head and neck are extranodal [2]. These lym-
hoid tumors mainly involve 4 sites: Waldeyer’s ring, the nasal
inuses and fossae, the oral cavity and the salivary glands.
Extranodal lymphoma comprises a heterogeneous group of
umors of various histologic types and highly varied clinical pre-
entation. Diagnosis may  fail to be suspected when the clinical
nd/or radiological tumoral syndrome mimics epithelial tumor or
nfection, but needs to be considered as treatment is speciﬁc.
∗ Corresponding author.
E-mail address: christine.bach@hopital-foch.org (C.A. Bach).
http://dx.doi.org/10.1016/j.anorl.2014.07.005
879-7296/© 2014 Elsevier Masson SAS. All rights reserved.The present study sought to describe the characteristics of
patients with extranodal lymphoma of the head and neck (ELHN),
highlighting the polymorphic clinical presentation and the role of
the ENT physician in the optimization of management.
2. Materials and methods
Files of all patients presenting with ELHN between January
1st, 2001 and December 31st, 2013 were analyzed retrospectively,
excluding intra- and juxta-parotid nodal locations.
Deﬁnitive diagnosis was  histologic. Pathology exams were
analyzed according to their code on the ADICAP classiﬁcation
(Association pour le Développement de l’Informatique en Cytolo-
gie et en Anatomie Pathologique: Association for the Development
of Informatics in Cytology and Anatomo-Pathology), enabling all
extranodal locations (excluding code SG: [node]) of the head and
neck to be selected: codes AA (amygdala), XF (face), AC (nasopha-
rynx), XC (cervical region), AF (nasal fossae), AS (facial sinus), OE
(eye), BX (oral cavity), AL (larynx), BL (tongue) and BP (parotid).
The WHO  2009 classiﬁcation was used for characterizing
histologic type: B-cell, T-cell or lymphocytic (LCL) lymphoma
or plasmacytoma. B-cell lymphoma was  classiﬁed as: MALT
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Table  1
Frequency of histologic types of ELHN.
Histologic type Number Frequency (%)
B-cell lymphoma,
n = 56
Diffuse large B-cell
lymphoma (DLBCL)
36 54
MALT B-cell lymphoma 6 9
Lymphocytic
lymphoma (LCL)
4 6
Brain B-cell lymphoma 4 6
Burkitt’s B-cell
lymphoma
3  4.5
Centroblastic B-cell
lymphoma
2 3
Low-grade B-cell
lymphoma
1 1.5
T-cell lymphoma,
n = 4
T/NK nasal lymphoma 3 4.5
Angioimmunoblastic
T-cell lymphoma
1 1.5
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Fig. 1. A: Temporal bone CT scan, axial slice. Temporal bone plasmacytoma: severe
bone lysis, in contrast to relatively silent symptomatology: hearing loss and vesti-
bular hyper-reﬂexivity of progressive onset over several months. B: cervical MRI,Plasmacytoma 5 7
Undetermined 2 3
mucosa-associated lymphoid tissue) lymphoma, small-cell cere-
ral lymphoma, Burkitt’s lymphoma, CD20+ diffuse large B-cell
ymphoma (DLBCL), centroblastic B-cell lymphoma or other low-
rade B-cell lymphomas T-cell lymphoma was  classiﬁed as
 angioimmunoblastic T-cell lymphoma or angiocentric T/NK-cell
asal lymphoma.
Lymphomas were further classiﬁed as aggressive or indolent.
DLBCL, Burkitt’s and T/NK-cell lymphomas are highly malig-
ant and aggressive. Lymphoma associated with HIV is generally
ighly malignant. Follicular, low-grade B-cell, brain cell, LCL, MALT
ymphomas and plasmacytoma are of low malignancy or indolent.
Age at diagnosis, gender, histologic type, location, type of clinical
resentation, time interval between symptom onset and histologic
iagnosis and known risk factors (HIV-positive status and history
f immune disorder) were recorded.
The presenting symptom leading to diagnosis was  recorded
nd counted as the clinical presentation. B symptoms and cervical
denopathies were recorded; B symptoms comprise general symp-
oms: fever, night sweats and weight-loss, associated with both
odgkin and non-Hodgkin lymphoma.
The specialization (ENT or other) of the physician seen for
he presenting symptom leading to diagnosis and of the physi-
ian taking the diagnostic sample was recorded in each case.
he type of sample enabling histologic diagnosis was classiﬁed
s surgical specimen (total or partial organ resection) or surgical
iopsy. Fine-needle aspiration ahead of diagnostic biopsy was also
ecorded.
All patients underwent local and remote imaging. Fig. 1A and
 shows two examples (CT and MRI) of a temporal plasmacytoma
nd a thyroid lymphoma. The images are not pathology-speciﬁc
nd contrasted with the respective clinical presentations.
. Results
Sixty-seven ELHNs were diagnosed in the department between
anuary 1st, 2001 and December 31st, 2013: 39 male and 28 female
atients (M/F sex ratio, 1.4), with a mean age of 65 years (range,
7–97 years). Fig. 2A shows incidence according to age.
B-cell lymphoma (n = 56, 84%) was more frequent than plasma-
ytoma (n = 5, 7%) or T-cell lymphoma (n = 4, 6%). Table 1 shows
requency according to histologic type.
The most frequent histologic type was DLBCL, a high-grade B-
ell lymphoma (n = 36). MALT B-cell lymphoma was systematically
arotid (n = 6) and LCL systematically tonsillar (n = 4). There were
o cases of Hodgkin lymphoma.axial slice: thyroid DLBCL: left thyroid mass pushing back and invading trachea.
Inspiratory dyspnea requiring intensive care.
T-cell lymphoma comprised T/NK nasal lymphoma (n = 3) and
angioimmunoblastic T-cell lymphoma (n = 1). T/NK lymphoma was
systematically EBV-positive, with sinonasal location; the angioim-
munoblastic T-cell lymphoma was nasopharyngeal.
The most frequent ELHN locations were: palatine tonsil (n = 19,
27%), nasal fossa and sinus (n = 13, 19%), nasopharynx (n = 10, 14%)
and parotid gland (n = 9, 13%). Other locations comprised tongue,
soft palate, face, orbit, thyroid, lingual tonsil, temporal bone and
larynx. Four patients had 2 extranodal locations of simultaneous or
consecutive onset: 1 hypophyseal LCL with concomitant tonsillar
LCL; 1 basilingual DLBCL 9 years after rhinopharyngeal DLBCL; 1
left parotid MALT lymphoma 6 years after right parotid MALT lym-
phoma; and 1 tonsillar DLBCL 4 years after sinonasal DLBCL. ELHN
locations are shown in Fig. 2B.
A. Picard et al. / European Annals of Otorhinolaryngol
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Pig. 2. A: Number of ELHNs according to patient age at diagnosis. B: anatomic
ocation of ELHN.
Presenting symptoms comprised a mass or locally increased
olume (n = 22, 33%), pain (n = 4, 6%), and B symptoms (n = 6,
%); without visible or palpable mass, presenting symptoms were
elated to tumor location in 52% of cases: nasal obstruction,
dynophagia, pharyngeal discomfort, dysphagia, dysphonia, etc.
linical presentations are shown in Table 2.
Mean interval time between symptom onset and deﬁnitive his-
ologic diagnosis was 6 months (median, 3 months; range, 7 days
o 5 years).
Involvement was strictly extranodal head and neck in 37 cases
55%); 24 (36%) had associated cervical lymph-node involvement,
able 2
resenting symptom.
Number of
patients
Frequency
(%)
Mass 22 33
Pain 4 6
B symptoms
n  = 6.9%
Weight-loss 4 6
Night-sweats/fever 2 3
Mass location
related
symptoms
n  = 35, 52.2%
Odynophagia/pharyngeal
discomfort
11 16.4
Nasal obstruction 6 9
Epistaxis 4 6
Dyspnea/dysphonia 3 4.5
Tinnitus/vertigo 2 3
Seromucous otitis 2 3
Exophthalmia 2 3
Recurrent sinusitis 1 1.5
Dysphagia 1 1.5
Blindness 1 1.5
SAS 1 1.5
Other 1 1.5
Total 67 100ogy, Head and Neck diseases 132 (2015) 71–75 73
and 10 (15%) associated involvement outside the head and neck
region. Two  patients were HIV-positive.
Aggressive lymphoma (n = 43) was  associated with cervical
lymph nodes in 40% of cases (n = 17) and with involvement beyond
the head and neck region in 16% (n = 7). Mean time between symp-
tom onset and diagnosis of aggressive lymphoma was 3.9 months.
Fine-needle aspiration was associated in 18.6% of cases.
Indolent lymphoma (n = 23) was  associated with cervical
adenopathies in 39% of cases (n = 9) and with involvement outside
the head and neck region in 13% (n = 3). Mean interval time between
symptom onset and diagnosis was  10.3 months. Fine-needle aspi-
ration was  associated in 43.5% of cases.
Eight of the 67 patients (12%) had been treated in the hemato-
logy department for lymphoproliferative disorder before diagnosis
of head and neck lesion.
Sixty-seven percent of patients initially consulted an ENT
physician; 21% had consulted an internal medicine/hematology
specialist, and 7% another specialist (2 ophthalmologists, 1 endocri-
nologist, 1 stomatologist and 1 emergency physician); the specialty
of the physician initially consulted was  unknown in 3 cases.
Diagnosis was  systematically conﬁrmed on histology: partial or
total organ specimen in 54% of cases (n = 36) and surgical biopsy
in 46% (n = 31). Pre-sampling ﬁne-needle aspiration was feasible
in only 46% of cases and actually performed in 24%; cytology
found lymphoma in 31% of cases was uncertain in 44% and non-
contributive in 25%.
4. Discussion
Extranodal lymphoma of the head and neck is rare: our
ENT department receives 12,000 patients per year, and over the
last 13 years only 67 ELHNs have been diagnosed (i.e., 5 per
year). This incidence matches those of single-center retrospec-
tive studies published since 1986: 1.9 to 11.4 cases per year
[2–13].
This type of lymphoma affects patients with a median age of 68
years, with peak incidence in the 6th and 7th decades, although all
ages may  be concerned. Patients are more often male (M/F sex ratio
1.4 in the present series).
There were no cases of Hodgkin lymphoma in the present series.
Hodgkin ELHN is extremely rare, at less than 0.9% of Hodgkin lym-
phomas [14].
The most frequent location in the present series was the palatine
tonsils (27%). Other studies reported rates of 22–54% [3–5,8,11,13].
Waldeyer’s ring, a lymphoid structure, is reported top be a frequent
ELHN site (41% of cases).
The most frequent histologic type was large B-cell lymphoma
(54%), as in Western and Japanese reports (34–72%) [8,11–13].
T/NK-cell nasal lymphoma is more common in Asia and Latin Amer-
ica, and is the most frequent histologic type in China [10,15].
Clinical presentation is non-speciﬁc. ELHN shows as a mass or in
symptoms related to the location of the mass (in 85% of cases in the
present series). Clinical presentation is very heterogeneous, varying
with location [4,8], and may  be explosive or insidious according to
histologic type.
Symptomatology is patent in aggressive lymphomas such as
DLBCL or Burkitt’s lymphoma, and may  require intensive care.
Tumor mass increases rapidly, doubling in 24–48 hours in some
cases [16]. The interval between onset and histologic diagnosis is
very short (1–3 months on average).
In contrast, indolent lymphomas (plasmacytoma, cerebral lym-
phoma of the brain and MALT lymphoma) show an insidious
presentation. Symptomatology becomes chronic and onset-to-
diagnosis interval is much longer (a mean 9, 13 and 17 months
respectively in the present series).
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T/NK-cell nasal lymphoma is a special case. It is aggressive, with
oor prognosis (overall 5-year survival, 42% [17]); the sinonasal
linical presentation is relatively silent: nasal obstruction, sinusitis,
hinorrhea, epistaxis, etc. In the literature as in the present series,
 symptoms are absent, there is little or no pain, and onset-to-
iagnosis time is long (11 months in the present series, and up to
4 months elsewhere [18]). Few studies, however, have focused on
linical presentation in these cases, and a larger patient base would
e needed to support any conclusions.
Unlike nodal forms, ELHN is rarely revealed by general signs. B
ymptoms do not dominate clinical presentation, constituting the
resenting symptom in only 7% of the present series and 1.6% in
hefﬁeld’s report [8], which was limited to “localized” forms, with
o associated involvement beyond the head and neck region (ver-
us 15% in the present series), which may  account for the lower rate
f B symptoms.
T/NK-cell nasal ELHN is rare in European populations; the
resent series included 3 cases. Males are more often affected:
ll 3 of the present cases, and two-thirds in the literature [15].
ocation is predominantly sinonasal (2 nasal fossa locations in the
resent 3 cases interval). There may  be contiguous extension to
djacent structures, as in 1 of the present 3 cases. Rare nasopharyn-
eal, oropharyngeal, laryngeal and even non-head and -neck (skin,
igestive tract, etc.) locations have been reported [18]. Etiology
emains unclear, but there is a deﬁnite link with EBV: a litera-
ure review reported 90–100% of T/NK-cell nasal lymphomas were
BV-positive [15] (100% in the present series).
Only 1.2% of Burkitt’s lymphomas are ELHN [16] (3 in the present
eries). They occur in younger patients (mean 27 years in the
resent series, and a median 46 years, taking all locations together,
n the literature [16]).
Extramedullary head and neck plasmacytoma is rare; there are
ew studies, with small series. It is an indolent hemopathy, of
low evolution and relatively silent clinical presentation. Onset-
o-histology time is long: 7.5 months in a retrospective study of 46
ases [19], and about 9 months in the present series. There is male
redominance: 1.5 in the present series and 1.7–4 in the literature
19–21]. There were no sinonasal location in the present series,
ompared to 40–43% in the literature [19–21]. Other locations are
hose previously mentioned: nasopharynx (18–20%), oropharynx
18%) and larynx (6–18%) [19–21]. Exceptional temporal bone loca-
ion has been reported.
Thyroid lymphoma is revealed by goiter, with few if any B symp-
oms [22]. The two main histologic types are MALT lymphoma
nd DLBCL [22]. The present series included 2 cases of thyroid
ymphoma. Presentation was highly patent, with inspiratory dys-
nea and compressive goiter with or without recurrent nerve palsy
equiring intensive care. Mean onset-to-histology time was short:
.5 months. The literature reports female predominance (1.83 to
.6 [23]), especially in case of history of Hashimoto’s thyroiditis
relative risk, 67 [24]); the present cases were 1 man  and 1 woman,
ithout history of immune disorder or thyroiditis.
These differences were probably due to the present 2 cases
eing DLBCL. In thyroid lymphoma, DLBCL shows a clinical pre-
entation highly distinct from MALT lymphoma. It is less rare in
ales (2 males to 11 females, versus 0 males to 6 females for
ALT lymphoma), the goiter is larger, B symptoms are more com-
on and history of thyroiditis is rarer [23]. Hashimoto’s thyroiditis
ould seem to predispose toward MALT lymphoma rather than
ther histologic types: 92% of MALT lymphomas involved history of
ashimoto’s thyroiditis, versus only 40% for other histologic types
22].
Parotid lymphoma is usually of MALT form: 27.9% in the lit-
rature [8,25], and 66% in the present series. There is female
redominance: 1.5 in the present series, and 1.4 in a study of 2140
arotid lymphomas [25]. Revelation is by a progressively enlargingogy, Head and Neck diseases 132 (2015) 71–75
parotid mass (8 of the present 9 cases, the other being serendip-
itously discovered on imaging). It causes paresis or facial palsy
in 4–15% of cases [25], although there were no such cases in the
present series. Clinical presentation is usually an aspect of benign
parotid tumor. In the present series, one-third of the patients (1
male, 2 females) had history of Sjögren’s syndrome. In parotid lym-
phoma, history of immune disorder such as Sjögren’s syndrome
is more frequent than in the general population and may  induce
lymphoproliferative disorder, in turn inducing parotid lymphoma
[25].
In the present series, aggressive lymphomas showed rapid evo-
lution, were frequently disseminated (head and neck lymph nodes
and non-head and -neck locations), with patent symptomatology
and short onset-to-diagnosis times (mean, 4 months). Emergency
treatment was required in some cases. Fine-needle aspiration was
performed in at least 20% of cases. Rapid diagnosis was mandatory
to initiate treatment. In indolent lymphomas, onset-to-diagnosis
time was  longer (mean, 10 months). The symptomatology of a
chronically evolving mass without impaired general health sta-
tus does not incite early consultation. Fine-needle aspiration was
performed in almost half of the cases (43.5%).
In the present series, 85% of NLHN patients had symptoms incit-
ing ENT consultation: indolent head and neck mass (33% of cases) or
ENT symptomatology related to the location of the mass (52%), usu-
ally without impaired general health status. An ENT physician was
consulted initially in 67% of cases, and an ENT physician took the
diagnostic sample in 97%. More than half of the lesions were inac-
cessible to ﬁne-needle aspiration, especially when there were no
associated cervical adenopathies. In 22% of cases, ﬁne-needle aspi-
ration was not performed despite being feasible, due to easy access
for tissue biopsy, context (e.g., history of lymphoproliferative disor-
der) or diagnostic urgency. In 25% of cases, it was non-contributive
and of uncertain interpretation in almost half the cases (44%); one-
third of cytology ﬁndings suggested lymphoma.
Suggested diagnosis of lymphoma by an ENT specialist in case
of a non-speciﬁc aspect of tumor or positive ﬁne-needle aspiration
cytology optimizes management of ELHN, orienting the report to
the patient, scheduling ﬂow cytometry of the histology specimen,
tumor biopsy in sufﬁcient quantity to detect the various tumor
markers, and osteomedullary biopsy under general anesthesia in
the same step as the tumor biopsy.
5. Conclusion
Extranodal lymphoma of the head and neck is rare. Clinical pre-
sentation varies greatly according to location and histologic type.
ENT physicians should be able to make this diagnosis, whatever
the anatomic location, so as to optimize diagnostic management.
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